Exploitation of host signaling pathways by B cell superantigens - Potential strategies for developing targeted therapies in systemic autoimmunity

Annals of the New York Academy of Sciences

Volumn 1095, Issue , 2007, Pages 342-354

  Zouali, Moncef ^a,b  

^a INSERM   (France)

^b CENTRE VIGGO PETERSEN   (France)

Author keywords

Autoimmunity; B cell repertoire; B 1a cells; HIV 1 gp120; Innate immunity; Marginal zone cells; P. magnus protein L; S. aureus protein A; Superantigen

Indexed keywords

AUTOANTIBODY; B LYMPHOCYTE ANTIBODY; B LYMPHOCYTE ANTIGEN; SUPERANTIGEN;

AUTOIMMUNITY; B LYMPHOCYTE; CELL SUBPOPULATION; CONFERENCE PAPER; HOST CELL; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; AUTOIMMUNE DISEASE; IMMUNOLOGY; MICROBIOLOGY; REVIEW; VIROLOGY;

ANIMALIA; FINEGOLDIA MAGNA; HUMAN IMMUNODEFICIENCY VIRUS 1; STAPHYLOCOCCUS AUREUS;

ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; SIGNAL TRANSDUCTION; SUPERANTIGENS;

EID: 34247842802     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1397.038     Document Type: Conference Paper

References (43)

1. HASLER, P. & M. ZOUALI. 2003. Subversion of B lymphocyte signaling by infectious agents. Genes Immun. 4: 95-103.
2. MARRACK, P. & J. KAPPLER. 1990. The staphylococcal enterotoxins and their relatives. Science 248: 705-711.
3. SCHLIEVERT, P.M., A.P. ASSIMACOPOULOS & P.P. CLEARY. 1996. Severe invasive group A streptococcal disease: clinical description and mechanisms of pathogenesis. J. Lab. Clin. Med. 127: 13-22.
4. IMBERTI, L., A. SOTTINI, A. BETTINARDI, et al. 1991. Selective depletion in HIV infection of T cells that bear specific T cell receptor V beta sequences. Science 254: 860-862.
5. DALGLEISH, A.G., S. WILSON, M. GOMPELS, et al. 1992. T-cell receptor variable gene products and early HIV-1 infection. Lancet 339: 824-828.
6. STEFANOVA, I. et al. 1996. HIV infection-induced posttranslational modification of T cell signaling molecules associated with disease progression. J. Clin. Invest. 98: 1290-1297.
7. TRIMBLE, L.A. & J. LIEBERMAN. 1998. Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling chain of the T-cell receptor complex. Blood 91: 585-594.
8. GIOVANNETTI, A., M. PIERDOMINICI, F. MAZZETTA, et al. 2000. HIV type 1-induced inhibition of CD45 tyrosine phosphatase activity correlates with disease progression and apoptosis, but not with anti-CD3-inducedTcell proliferation. AIDS Res. Hum. Retroviruses 16: 211-219.
9. LAURENCE, J., A.S. HODTSEV & D.N. POSNETT. 1992. Superantigen implicated in dependence of HIV-1 replication in T cells on TCR V beta expression. Nature 358: 255-259.
10. WEINHOLD, K.J., H.K. LYERLY, S.D. STANLEY, et al. 1989. HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J. Immunol. 142: 3091-3097.
11. MORIO, T., T. CHATILA & R.S. GEHA. 1997. HIV glycoprotein gp120 inhibits TCR-CD3-mediated activation of fyn and lck. Int. Immunol. 9: 53-64.
12. GOLDMAN, F., J. CRABTREE, C. HOLLENBACK & G. KORETZKY. 1997. Sequestration of p56(lck) by gp120, a model for TCR desensitization. J. Immunol. 158: 2017-2024.
13. ZOUALI, M. 1995. B-cell superantigens: implications for selection of the human antibody repertoire. Immunol. Today 16: 399-405.
14. BERBERIAN, L., L. GOODGLICK, T.J. KIPPS & J. BRAUN. 1993. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 261: 1588-1591.
15. ZOUALI, M. 1994. Unravelling antibody genes. Nat. Genet. 7: 118-120.
16. KARRAY, S. & M. ZOUALI. 1997. Identification of the B cell superantigen-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA 94: 1356-1360.
17. KARRAY, S., L. JUOMPAN, R.C. MAROUN, et al. 1998. Structural basis of the gp120 superantigen-binding site on human immunoglobulins. J. Immunol. 161: 6681-6688.
18. BESSUDO, A., L. RASSENTI, D. HAVLIR, et al. 1998. Aberrant and unstable expression of immunoglobulin genes in persons infected with human immunodeficiency virus. Blood 92: 1317-1323.
19. SCAMURRA, R.W., D.J. MILLER, L. DAHL, et al. 2000. Impact of HIV-1 infection on VH3 gene repertoire of naive human B cells. J. Immunol. 164: 5482-5491.
20. JUOMPAN, L., P. LAMBIN & M. ZOUALI. 1998. Selective alterations of the antibody response to HIV-1. Appl. Biochem. Biotechnol. 75: 139-150.
21. JUOMPAN, L., P. LAMBIN & M. ZOUALI. 1998. Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection. FASEB J. 12: 1473-1480.
22. VIAU, M. & M. ZOUALI. 2001. Molecular determinants of the human antibody response to HIV-1: implications for disease control. J. Clin. Immunol. 21: 410-419.
23. CHANG, Q., J. ABADI, P. ALPERT & L. PIROFSKI. 2000. A pneumococcal capsular polysaccharide vaccine induces a repertoire shift with increased VH3 expression in peripheral B cells from human immunodeficiency virus (HIV)-uninfected but not HIV-infected persons. J. Infect. Dis. 181: 1313-1321.
24. VIAU, M., N.S. LONGO, P.E. LIPSKY, et al. 2004. Specific in vivo deletion of B-cell subpopulations expressing human immunoglobulins by the B-cell superantigen protein L. Infect. Immun. 72: 3515-3523.
25. KASTERN, W., E. HOLST, E. NIELSEN, et al. 1990. Protein L, a bacterial immunoglobulin-binding protein and possible virulence determinant. Infect. Immun. 58: 1217-1222.
26. BJORCK, L. 1988. Protein L. A novel bacterial cell wall protein with affinity for Ig L chains. J. Immunol. 140: 1194-1197.
27. NILSON, B.H., A. SOLOMON, L. BJORCK & B. AKERSTROM. 1992. Protein L from Peptostreptococcus magnus binds to the kappa light chain variable domain. J. Biol. Chem. 267: 2234-2239.
28. NICHOLSON, I.C. et al. 1999. Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes. J. Immunol. 163: 6898-6906.
29. VIAU, M., N.S. LONGO, P.E. LIPSKY & M. ZOUALI. 2005. Staphylococcal protein A deletes B-1a and marginal zone B lymphocytes expressing human immunoglobulins: an immune evasion mechanism. J. Immunol. 175: 7719-7727.
30. GOODYEAR, C.S. & G.J. SILVERMAN. 2004. Staphylococcal toxin induced preferential and prolonged in vivo deletion of innate-like B lymphocytes. Proc. Natl. Acad. Sci. USA 101: 11392-11397.
31. GAULD, S.B., J.M. DAL PORTO & J.C. CAMBIER. 2002. B cell antigen receptor signaling: roles in cell development and disease. Science 296: 1641-1642.
32. WIKSTROM, M., T. DRAKENBERG, S. FORSEN, et al. 1994. Three-dimensional solution structure of an immunoglobulin light chain-binding domain of protein L. Comparison with the IgG-binding domains of protein G. Biochemistry 33: 14011-14017.
33. GRAILLE, M. et al. 2001. Complex between Peptostreptococcus magnus protein L and a human antibody reveals structural convergence in the interaction modes of Fab binding proteins. Structure (Camb.) 9: 679-687.
34. VIAU, M., B. CHOLLEY, L. BJORCK & M. ZOUALI. 2004. Down-modulation of the antigen receptor by a superantigen for human B cells. Immunol. Lett. 92: 91-96.
35. SMITH, D., R. D'ARGY, M. NILSSON, et al. 2004. Whole-body autoradiography reveals that the Peptostreptococcus magnus immunoglobulin-binding domains of protein L preferentially target B lymphocytes in the spleen and lymph nodes in vivo. Cell Microbiol. 6: 609-623.
36. DAS, T., G. SA & P.K. RAY. 1999. Mechanisms of protein A superantigen-induced signal transduction for proliferation of mouse B cell. Immunol. Lett. 70: 43-51.
37. SELVEY, L.A., H.C. MORSE, III, C.H. JUNE & R.J. HODES. 1995. Analysis of antigen receptor signaling in B cells from mice with a retrovirus-induced acquired immunodeficiency syndrome. J. Immunol. 154: 171-179.
38. ZOUALI, M. & G. SARMAY. 2004. B lymphocyte signaling pathways in systemic autoimmunity: implications for pathogenesis and treatment. Arthritis Rheum. 50: 2730-2741.
39. ZOUALI, M. 2005. Taming lupus. Sci. Am. 292: 58-65.
40. VIAU, M. & M. ZOUALI. 2005. B-lymphocytes, innate immunity, and autoimmunity. Clin. Immunol. 114: 17-26.
41. VIAU, M. & M. ZOUALI. 2005. Effect of the B cell superantigen protein A from S. aureus on the early lupus disease of (NZBxNZW) F1 mice. Mol. Immunol. 42: 849-855.
42. ENEVER, C., I.M. TOMLINSON, J. LUND, et al. 2005. Engineering high affinity superantigens by phage display. J. Mol. Biol. 347: 107-120.
43. BADR, G., G. BORHIS, D. TRETON, et al. 2005. HIV type 1 glycoprotein 120 inhibits human B cell chemotaxis to CXC chemokine ligand (CXCL) 12, CC chemokine ligand (CCL)20, and CCL21. J. Immunol. 175: 302-310.